对特应性皮炎发病机制的认识催生新获批的系统性疗法
特应性皮炎(AD)以鳞屑、渗出和瘙痒为特征,中重度患者治疗选择长期有限,环孢素A曾是多数欧洲国家唯一获批的系统性免疫抑制剂。随着对AD病理生理理解的深入,2017年首个生物制剂获批后,过去3年内欧洲和美国又新增4种系统性疗法获批,治疗格局发生重大转变。本综述强调关键突破如何推动2型免疫靶向生物制剂、神经免疫调节剂和Janus激酶抑制剂的探索。
要点
- 中重度AD治疗选择长期有限,环孢素A曾是多数欧洲国家唯一获批的系统性免疫抑制剂。
- 2017年首个AD生物制剂获批后,过去3年内欧洲和美国又有4种系统性疗法获批。
- 对AD病理生理的理解推动了2型免疫靶向生物制剂、神经免疫调节剂和Janus激酶抑制剂的探索。
核心结论
- 对AD病理生理关键突破的理解已转变其治疗格局,推动2型免疫靶向生物疗法扩展、神经免疫调节剂探索及对Janus激酶抑制的兴趣。
研究设计与样本
- 本文为综述,总结AD发病机制认识进展如何促成新获批的系统性疗法。
主要发现
- 中重度AD治疗选择历史上非常有限,超说明书用药是常见管理方式。
- 数十年来环孢素A是多数欧洲国家唯一获批用于AD的系统性免疫抑制药物。
- 2017年首个AD生物疗法获批后,过去3年内欧洲和美国又有4种系统性疗法获批。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by scaly, oozing skin and itch. In moderate-to-severe AD, treatment options have been historically very limited and off-label use has been a common method for disease management. For decades, ciclosporin A was the only systemic immunosuppressive drug approved in most European countries to address this major unmet medical need. However, increased understanding of the pathophysiology of AD has led to a revolution in the treatment of this potentially debilitating disease. Following the approval of the first biological therapy for AD in 2017, there has been a rapid expansion of compounds under development and four additional systemic therapies have been approved in Europe and the USA within the past 3 years alone. In this review, we underscore how key breakthroughs have transformed the therapeutic landscape of AD, leading to a major expansion of type 2 immunity-targeted biological therapies, exploration of neuroimmune modulatory agents, and interest in Janus kinase inhibition.
引用
- Trier AM, Kim BS. Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies. Br J Dermatol. 2023. PMID: 36763703. doi:10.1093/bjd/ljac016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。